SOURCE: Bellwether Report

June 22, 2005 12:16 ET

BWR Issues Morning Alerts for Shareholders of: DWCH, SVVS, EYET, and GNLB

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by The Bellwether Report.

TORONTO -- (MARKET WIRE) -- June 22, 2005 -- The Bellwether Report is the leading online financial newsletter, focusing on small-cap emerging growth opportunities. We strive to introduce investors to truly undervalued opportunities in a time-friendly fashion, allowing for optimal entry points and profitable exit points. Today, BWR will be evaluating the mornings four most promising companies on the Nasdaq Exchange. Datawatch (NASDAQ: DWCH), SAVVIS (NASDAQ: SVVS), Eyetech pharmaceuticals (NASDAQ: EYET) and Genelabs Technology (NASDAQ: GNLB). For more information on BWR or any of the above-mentioned companies, feel free to visit for a free no obligation 30-day trial of our service.

Datawatch announced today the availability of Visual/Productivity Portal for IBM WebSphere, featuring employee self help. Visual Productivity Portal enables personalized self help for an organization's employees, dramatically reducing unnecessary phone calls, log entries and related processing. Today's news caused stocks to increase 93% in early trading. BWR will be tracking the progress of this company for the next 30 days to see if today's influx in demand is a result of this corporate development.

SAVVIS today announced and demonstrated a new desktop utility computing service. It will integrate the Sun Microsystems Sun Ray thin client technology with SAVVIS Virtualized IT utility services platform and management. Shares rose nearly 16% in early morning trading and BWR will be following this company over the following weeks to assess the short- and long-term affect of today's announcement.

Eyetech pharmaceuticals announced today that as a result of the sales of Macugen they have revised their 2005 forward-looking guidance for net product revenue. The company now expects revenue to be in the range of $175-$190 million compared to previous estimates of $135-$150 million. Today's announcement pleased investors, as shares rose $1.05 from its previous close. BWR will continue monitoring this company's success to see if their prediction comes true.

Genelabs Technology announced today that they will be releasing an update on the development of Prestara, its investigational drug for lupus. Investors showed interest in this company today as Genelabs traded nearly ten times their average volume and traded up 35%. BWR will keep this company on their radar screen for any further developments.

Any information that we find on the above-mentioned companies will be posted at

For 30 days complimentary with the BWR service, feel free to visit and sign up. No credit card needed!!

The Bellwether Report to date has not been compensated by any of the above-mentioned companies.

Contact Information

  • For More information contact:
    The Bellwether Report
    1 877 702 1828
    Email Contact